Posted On: 07/01/2016 9:08:05 PM
Post# of 273351
Phosphagenics SP ADR (PPGNY) 0.5750 $PPGNY
Pruritus Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/gp95f6/pruritus) has announced the addition of the "Pruritus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pruritus Overview - Therapeutics Development - Pipeline Products for Pruritus - Overview - Pipeline Products for Pruritus - Comparative Analysis - Pruritus - Therapeutics under Development by Companies - Pruritus - Therapeutics under Investigation by Universities/Institutes - Pruritus - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pruritus - Products under Development by Companies - Pruritus - Products under Investigation by Universities/Institutes - Pruritus - Companies Involved in Therapeutics Development - AlbireoPharma - Amorepacific Corporation - Cara Therapeutics, Inc. - Chugai Pharmaceutical Co., Ltd. - Creabilis SA - ELORAC, Inc. - FAES Farma SA - GlaxoSmithKline Plc - Helsinn Healthcare S.A. - Hydra Biosciences, Inc. - LEO Pharma A/S - Merck & Co., Inc. - NeRRe Therapeutics Ltd - Nippon Shinyaku Co., Ltd. - Phosphagenics Limited - RDD Pharma Ltd. - Shionogi & Co., Ltd. - Tioga Pharmaceuticals, Inc. - Trevi Therapeutics, Inc. - Vanda Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/gp95f6/pruritus
VNDA: 11.43 (+0.24), MRK: 57.94 (+0.33), GSK: 43.17 (-0.17)
Global H2 2015 Peripheral Neuropathic Pain Pipeline Review
M2 - Mon Feb 01, 8:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/zn2q5h/peripheral) has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peripheral Neuropathic Pain Overview - Therapeutics Development - Pipeline Products for Peripheral Neuropathic Pain - Overview - Pipeline Products for Peripheral Neuropathic Pain - Comparative Analysis - Peripheral Neuropathic Pain - Therapeutics under Development by Companies - Peripheral Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes - Peripheral Neuropathic Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peripheral Neuropathic Pain - Products under Development by Companies - Peripheral Neuropathic Pain - Products under Investigation by Universities/Institutes - Peripheral Neuropathic Pain - Companies Involved in Therapeutics Development - AnaBios Corporation - Astellas Pharma Inc. - Eli Lilly and Company - GW Pharmaceuticals Plc - Nektar Therapeutics - Phosphagenics Limited - Sunovion Pharmaceuticals Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/zn2q5h/peripheral
LLY: 78.95 (+0.20), ZYNE: 6.93 (+0.08), NKTR: 14.40 (+0.17)
Acne Vulgaris Pipeline Review 2015
M2 - Wed Jan 27, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcgrnr/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acne Vulgaris Overview - Therapeutics Development - Pipeline Products for Acne Vulgaris - Overview - Pipeline Products for Acne Vulgaris - Comparative Analysis - Acne Vulgaris - Therapeutics under Development by Companies - Acne Vulgaris - Therapeutics under Investigation by Universities/Institutes - Acne Vulgaris - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acne Vulgaris - Products under Development by Companies - Acne Vulgaris - Products under Investigation by Universities/Institutes - Acne Vulgaris - Companies Involved in Therapeutics Development - 3SBio Inc. - Advancell - Allergan Plc - Almirall, S.A. - Biomar Microbial Technologies - Braintree Laboratories, Inc. - Brickell Biotech, Inc. - Celtaxsys, Inc. - Cosmo Pharmaceuticals S.p.A - Delenex Therapeutics AG - Deltanoid Pharmaceuticals Inc. - DermaXon, LLC - Dermira Inc. - ELORAC, Inc. - Ensol Biosciences Inc. - Foamix Pharmaceuticals Ltd. - Galderma S.A. - GlaxoSmithKline Plc - Helix BioMedix, Inc. - Hovione FarmaCiencia SA - Lee's Pharmaceutical Holdings Limited - Maruho Co., Ltd. - Novabiotics Limited - Novan, Inc. - OrigImm e.U. - Paratek Pharmaceuticals, Inc. - Phosphagenics Limited - Photocure ASA - Promius Pharma, LLC - Provectus Biopharmaceuticals, Inc. - RestorGenex Corporation - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - SkyePharma Plc - Telesso Technologies Limited - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/xc...e_vulgaris
FOMX: 6.60 (+0.25), GSK: 43.17 (-0.17), PRTK: 13.67 (-0.24), AGN: 234.02 (+2.93), PVCT: 0.37 (unch), DERM: 29.93 (+0.68)
Seborrhea Pipeline Review - H2 2015 Report
M2 - Wed Jan 27, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/nvlg4d/seborrhea) has announced the addition of the "Seborrhea - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Seborrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seborrhea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Seborrhea Overview - Therapeutics Development - Pipeline Products for Seborrhea - Overview - Pipeline Products for Seborrhea - Comparative Analysis - Seborrhea - Therapeutics under Development by Companies - Seborrhea - Therapeutics under Investigation by Universities/Institutes - Seborrhea - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Seborrhea - Products under Development by Companies - Seborrhea - Products under Investigation by Universities/Institutes - Seborrhea - Companies Involved in Therapeutics Development - Biomar Microbial Technologies - EpiPharm AG - Maruho Co., Ltd. - Phosphagenics Limited For more information visit http://www.researchandmarkets.com/research/nvlg4d/seborrhea
Phosphagenics Reports Positive Results for Weaner Pig Feed Efficiency Trial
BusinessWire - Wed Jan 20, 7:00AM CST
--TPM(R) outperforms standard Vitamin E as feed additive in first 14 days post weaning
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/b9sgcv/complicated_skin) has announced the addition of the "Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections cSSSI, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections cSSSI and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Complicated Skin And Skin Structure Infections cSSSI Overview - Therapeutics Development - Pipeline Products for Complicated Skin And Skin Structure Infections cSSSI - Overview - Pipeline Products for Complicated Skin And Skin Structure Infections cSSSI - Comparative Analysis - Complicated Skin And Skin Structure Infections cSSSI - Therapeutics under Development by Companies - Complicated Skin And Skin Structure Infections cSSSI - Therapeutics under Investigation by Universities/Institutes - Complicated Skin And Skin Structure Infections cSSSI - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Complicated Skin And Skin Structure Infections cSSSI - Products under Development by Companies - Complicated Skin And Skin Structure Infections cSSSI - Products under Investigation by Universities/Institutes - Complicated Skin And Skin Structure Infections cSSSI - Companies Involved in Therapeutics Development - CrystalGenomics, Inc. - Debiopharm International S.A. - Dong-A Socio Group - GlaxoSmithKline Plc - Melinta Therapeutics, Inc - MicuRx Pharmaceuticals, Inc. - Motif Bio Plc - Phosphagenics Limited For more information visit http://www.researchandmarkets.com/research/b9...cated_skin
GSK: 43.17 (-0.17)
Global Acute Pain Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/k9flzp/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Pain Overview - Therapeutics Development - Pipeline Products for Acute Pain - Overview - Pipeline Products for Acute Pain - Comparative Analysis - Acute Pain - Therapeutics under Development by Companies - Acute Pain - Therapeutics under Investigation by Universities/Institutes - Acute Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Pain - Products under Development by Companies - Acute Pain - Products under Investigation by Universities/Institutes - Acute Pain - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - Amorsa Therapeutics Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - AskAt Inc. - Cara Therapeutics, Inc. - Centrexion Corporation - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Dompe Farmaceutici S.p.A. - Grunenthal GmbH - INSYS Therapeutics, Inc. - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt Plc - MEDRx Co., Ltd. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Orexo AB - Orion Oyj - Pacira Pharmaceuticals, Inc. - Phosphagenics Limited - Recro Pharma, Inc. - Shulov Innovative Science Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. For more information visit http://www.researchandmarkets.com/research/k9flzp/acute_pain
ACRX: 2.69 (unch), KMPH: 4.32 (+0.34), NKTR: 14.40 (+0.17), INSY: 13.47 (+0.53), AVXL: 5.89 (-0.22), PCRX: 33.48 (-0.25), REPH: 8.18 (+0.23), PTIE: 2.17 (-0.02)
Phosphagenics Initiates Arbitration against Mylan
BusinessWire - Wed Jan 06, 6:00AM CST
Australian biotechnology company, Phosphagenics Limited (ASX
OH; OTCQX PGNY), announced today that it has commenced legal action against Mylan Laboratories Limited (Mylan), a wholly-owned subsidiary of Mylan Incorporated, by filing notices of arbitration at the Singapore International Arbitration Centre.
MYL: 43.48 (+0.24)
Osteoarthritis Pain Therapeutics Pipeline Review, H2 2015 - 29 Companies & 50 Drug Profiles
M2 - Thu Dec 17, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/v8nbgw/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Allergan Plc - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bone Medical Limited - Centrexion Corporation - Convergence Pharmaceuticals Ltd. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Flexion Therapeutics, Inc. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA Drug Profiles - (lidocaine hydrochloride tetracaine hydrochloride) - (naltrexone hydrochloride oxycodone hydrochloride) SR - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - capsaicin - cebranopadol - celecoxib - CGS-125 - CR-4056 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - MEDI-7352 - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A For more information visit http://www.researchandmarkets.com/research/v8...oarthritis
FLXN: 15.40 (+0.43), PFE: 35.57 (+0.36), AMGN: 154.28 (+2.13), AMPE: 1.29 (unch), LLY: 78.95 (+0.20), NKTR: 14.40 (+0.17), AGN: 234.02 (+2.93), AZN: 30.42 (+0.23), ABBV: 62.71 (+0.80), POZN: 5.94 (-0.43), REGN: 358.50 (+9.27), PTIE: 2.17 (-0.02)
The Anesthetic Effect Pipeline Review, H2 2015 - 16 Companies & 24 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/25xt8p/anesthetic_effect) has announced the addition of the "Anesthetic Effect - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anesthetic Effect, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anesthetic Effect and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Drug Profiles - (lidocaine hydrochloride phenylephrine hydrochloride tropicamide) - (tetracaine hydrochloride oxymetazoline hydrochloride) - ABP-700 - ADV-6209 - alphaxalone - bupivacaine hydrochloride - carboetomidate - Gabafol - HSK-3486 - lidocaine hydrochloride ER - LT-1121 - LT-1123 - methoxycarbonyl carboetomidate - methoxycarbonyl etomidate - neosaxitoxin - PB-5109 - PHY-301 - propofol - propofol microemulsion - propofol-DM - remimazolam - remimazolam - Small Molecules to Inhibit NMDA Receptor for Anaesthesia - sugammadex sodium Companies Mentioned - Advicenne Pharma - Biolab Sanus Farmaceutica Ltda. - Drawbridge Pharmaceuticals Pty Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Juniper Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Lipicard Technologies Limited - Merck & Co., Inc. - NanoMedex Pharmaceuticals, Inc. - Paion AG - Phosphagenics Limited - Physica Pharma SAS - Proteus SA - Sphaera Pharma Pvt. Ltd. - Taiwan Liposome Company, Ltd. - The Medicines Company For more information visit http://www.researchandmarkets.com/research/25...tic_effect
MRK: 57.94 (+0.33), JNP: 6.97 (-0.04)
Global Burns Therapeutics Pipeline Review 2015
M2 - Thu Dec 03, 7:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/phkvtr/burns_pipeline) has announced the addition of the "Burns - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burns, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burns and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adocia - AlgiPharma AS - Biogenomics Limited - Birken AG - CytoTools AG - Destiny Pharma Limited - HanAll Biopharma Co., Ltd. - Kuros Biosurgery AG - MediWound Ltd. - Novan, Inc. - Novartis AG - Pherecydes Pharma SA - Phosphagenics Limited - Se-cure Pharmaceuticals Ltd. - Stratatech Corporation - USV Limited - Vida Therapeutics Inc. - Xiber Science GmbH For more information visit http://www.researchandmarkets.com/research/ph...s_pipeline
MDWD: 7.86 (-0.03), NVS: 82.71 (+0.20)
ANI Pharmaceuticals Appoints Peter A. Lankau to Its Board of Directors
PR Newswire - Tue Oct 13, 7:00AM CDT
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) announced today the appointment of Peter A. Lankau to the Company's Board of Directors to fill the existing vacancy in the Board. Mr. Lankau has over 30 years of management experience in developing and commercializing pharmaceutical products.
ENDP: 16.98 (+1.39), ANIP: 57.31 (+1.49)
Acne Vulgaris Pipeline Review 2015 - 40 Companies & 53 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mtb2tv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advancell - Allergan, Inc. - AndroScience Corporation - Biomar Microbial Technologies - Braintree Laboratories, Inc. - Brickell Biotech, Inc. - Celtaxsys, Inc. - Cosmo Pharmaceuticals S.p.A - Cutanea Life Sciences - Delenex Therapeutics AG - Deltanoid Pharmaceuticals Inc. - Dermira Inc. - ELORAC, Inc. - Ensoltek Co., Ltd. - Foamix Pharmaceuticals Ltd. - Galderma S.A. - GlaxoSmithKline plc - Helix BioMedix, Inc. - Hovione FarmaCiencia SA - Kasiak Research Pvt. Ltd. - Lee's Pharmaceutical Holdings Limited - Maruho Co., Ltd. - Nabriva Therapeutics AG - Novabiotics Ltd - Novan, Inc. - OrigImm e.U. - Paratek Pharmaceuticals, Inc. - Phosphagenics Limited - Photocure ASA - Provectus Biopharmaceuticals, Inc. - QLT Inc. - RestorGenex Corporation - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Telesso Technologies Limited - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mt...e_vulgaris
QLTI: 1.44 (+0.02), FOMX: 6.60 (+0.25), GSK: 43.17 (-0.17), PRTK: 13.67 (-0.24), AGN: 234.02 (+2.93), PVCT: 0.37 (unch), DERM: 29.93 (+0.68), NBRV: 7.58 (+0.08)
Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics Pipeline Review, H1 2015 - 7 Companies & 11 Drug Profiles
M2 - Thu Jul 09, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vw27k3/complicated_skin) has announced the addition of the "Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cempra, Inc. - CrystalGenomics, Inc. - Debiopharm International S.A. - Dong-A Socio Group - GlaxoSmithKline plc - Melinta Therapeutics, Inc - Phosphagenics Limited Drug Profiles - CG-400549 - Debio-1450 - Debio-1452 - delafloxacin - fusidic acid - GSK-2140944 - iclaprim mesylate - lanopepden - Small Molecule for Skin Infections - Small Molecules to Inhibit DHFR for Infectious Diseases - tedizolid phosphate For more information visit http://www.researchandmarkets.com/research/vw...cated_skin
GSK: 43.17 (-0.17), CEMP: 17.09 (+0.60)
Seborrhea Pipeline Review, H1 2015 - 4 Companies & 6 Drug Profiles
M2 - Fri Jun 12, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pvb5km/seborrhea) has announced the addition of the "Seborrhea - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Seborrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seborrhea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Biomar Microbial Technologies - EpiPharm AG - Maruho Co., Ltd. - Phosphagenics Limited Drug Profiles - A-101 - EPI-SK14 - IB-07A081 - IB-07A085 - ketoconazole - lanoconazole For more information visit http://www.researchandmarkets.com/research/pvb5km/seborrhea
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 10.29 (-0.50), FOMX: 6.60 (+0.25), PVCT: 0.37 (unch), JNJ: 121.29 (-0.01), DERM: 29.93 (+0.68), ANAC: 99.06 (-0.14), XNCR: 18.93 (-0.06), REGN: 358.50 (+9.27), AQXP: 7.39 (+0.77), BMY: 73.78 (+0.23), GSK: 43.17 (-0.17), VRX.TO: 26.05 (-0.24), CBPO: 107.18 (+0.86), MRK: 57.94 (+0.33), CCXI: 4.74 (+0.25), CLTX: 36.01 (+16.34), CELGZ: 1.40 (-0.06), NVS: 82.71 (+0.20)
Seborrhea Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Fri Jan 02, 4:30PM CST
The report "Seborrhea Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Seborrhea. Seborrhea is a common skin problem. It causes a red, itchy rash and white scales. It particularly affects the sebaceous-gland-rich areas of skin such as scalp, face and torso. Seborrhoeic dermatitis symptoms appear gradually and usually the first signs are flaky skin and scalp. Adults of all ages may develop seborrhea, too, especially on the scalp and face. Complete Report is Available @ http://www.reportsnreports.com/reports/321896...-2014.html .
VRX.TO: 26.05 (-0.24)
Pruritus Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/gp95f6/pruritus) has announced the addition of the "Pruritus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pruritus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pruritus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pruritus Overview - Therapeutics Development - Pipeline Products for Pruritus - Overview - Pipeline Products for Pruritus - Comparative Analysis - Pruritus - Therapeutics under Development by Companies - Pruritus - Therapeutics under Investigation by Universities/Institutes - Pruritus - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pruritus - Products under Development by Companies - Pruritus - Products under Investigation by Universities/Institutes - Pruritus - Companies Involved in Therapeutics Development - AlbireoPharma - Amorepacific Corporation - Cara Therapeutics, Inc. - Chugai Pharmaceutical Co., Ltd. - Creabilis SA - ELORAC, Inc. - FAES Farma SA - GlaxoSmithKline Plc - Helsinn Healthcare S.A. - Hydra Biosciences, Inc. - LEO Pharma A/S - Merck & Co., Inc. - NeRRe Therapeutics Ltd - Nippon Shinyaku Co., Ltd. - Phosphagenics Limited - RDD Pharma Ltd. - Shionogi & Co., Ltd. - Tioga Pharmaceuticals, Inc. - Trevi Therapeutics, Inc. - Vanda Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/gp95f6/pruritus
VNDA: 11.43 (+0.24), MRK: 57.94 (+0.33), GSK: 43.17 (-0.17)
Global H2 2015 Peripheral Neuropathic Pain Pipeline Review
M2 - Mon Feb 01, 8:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/zn2q5h/peripheral) has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peripheral Neuropathic Pain Overview - Therapeutics Development - Pipeline Products for Peripheral Neuropathic Pain - Overview - Pipeline Products for Peripheral Neuropathic Pain - Comparative Analysis - Peripheral Neuropathic Pain - Therapeutics under Development by Companies - Peripheral Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes - Peripheral Neuropathic Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peripheral Neuropathic Pain - Products under Development by Companies - Peripheral Neuropathic Pain - Products under Investigation by Universities/Institutes - Peripheral Neuropathic Pain - Companies Involved in Therapeutics Development - AnaBios Corporation - Astellas Pharma Inc. - Eli Lilly and Company - GW Pharmaceuticals Plc - Nektar Therapeutics - Phosphagenics Limited - Sunovion Pharmaceuticals Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/zn2q5h/peripheral
LLY: 78.95 (+0.20), ZYNE: 6.93 (+0.08), NKTR: 14.40 (+0.17)
Acne Vulgaris Pipeline Review 2015
M2 - Wed Jan 27, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcgrnr/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acne Vulgaris Overview - Therapeutics Development - Pipeline Products for Acne Vulgaris - Overview - Pipeline Products for Acne Vulgaris - Comparative Analysis - Acne Vulgaris - Therapeutics under Development by Companies - Acne Vulgaris - Therapeutics under Investigation by Universities/Institutes - Acne Vulgaris - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acne Vulgaris - Products under Development by Companies - Acne Vulgaris - Products under Investigation by Universities/Institutes - Acne Vulgaris - Companies Involved in Therapeutics Development - 3SBio Inc. - Advancell - Allergan Plc - Almirall, S.A. - Biomar Microbial Technologies - Braintree Laboratories, Inc. - Brickell Biotech, Inc. - Celtaxsys, Inc. - Cosmo Pharmaceuticals S.p.A - Delenex Therapeutics AG - Deltanoid Pharmaceuticals Inc. - DermaXon, LLC - Dermira Inc. - ELORAC, Inc. - Ensol Biosciences Inc. - Foamix Pharmaceuticals Ltd. - Galderma S.A. - GlaxoSmithKline Plc - Helix BioMedix, Inc. - Hovione FarmaCiencia SA - Lee's Pharmaceutical Holdings Limited - Maruho Co., Ltd. - Novabiotics Limited - Novan, Inc. - OrigImm e.U. - Paratek Pharmaceuticals, Inc. - Phosphagenics Limited - Photocure ASA - Promius Pharma, LLC - Provectus Biopharmaceuticals, Inc. - RestorGenex Corporation - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - SkyePharma Plc - Telesso Technologies Limited - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/xc...e_vulgaris
FOMX: 6.60 (+0.25), GSK: 43.17 (-0.17), PRTK: 13.67 (-0.24), AGN: 234.02 (+2.93), PVCT: 0.37 (unch), DERM: 29.93 (+0.68)
Seborrhea Pipeline Review - H2 2015 Report
M2 - Wed Jan 27, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/nvlg4d/seborrhea) has announced the addition of the "Seborrhea - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Seborrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seborrhea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Seborrhea Overview - Therapeutics Development - Pipeline Products for Seborrhea - Overview - Pipeline Products for Seborrhea - Comparative Analysis - Seborrhea - Therapeutics under Development by Companies - Seborrhea - Therapeutics under Investigation by Universities/Institutes - Seborrhea - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Seborrhea - Products under Development by Companies - Seborrhea - Products under Investigation by Universities/Institutes - Seborrhea - Companies Involved in Therapeutics Development - Biomar Microbial Technologies - EpiPharm AG - Maruho Co., Ltd. - Phosphagenics Limited For more information visit http://www.researchandmarkets.com/research/nvlg4d/seborrhea
Phosphagenics Reports Positive Results for Weaner Pig Feed Efficiency Trial
BusinessWire - Wed Jan 20, 7:00AM CST
--TPM(R) outperforms standard Vitamin E as feed additive in first 14 days post weaning
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/b9sgcv/complicated_skin) has announced the addition of the "Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections cSSSI, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections cSSSI and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Complicated Skin And Skin Structure Infections cSSSI Overview - Therapeutics Development - Pipeline Products for Complicated Skin And Skin Structure Infections cSSSI - Overview - Pipeline Products for Complicated Skin And Skin Structure Infections cSSSI - Comparative Analysis - Complicated Skin And Skin Structure Infections cSSSI - Therapeutics under Development by Companies - Complicated Skin And Skin Structure Infections cSSSI - Therapeutics under Investigation by Universities/Institutes - Complicated Skin And Skin Structure Infections cSSSI - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Complicated Skin And Skin Structure Infections cSSSI - Products under Development by Companies - Complicated Skin And Skin Structure Infections cSSSI - Products under Investigation by Universities/Institutes - Complicated Skin And Skin Structure Infections cSSSI - Companies Involved in Therapeutics Development - CrystalGenomics, Inc. - Debiopharm International S.A. - Dong-A Socio Group - GlaxoSmithKline Plc - Melinta Therapeutics, Inc - MicuRx Pharmaceuticals, Inc. - Motif Bio Plc - Phosphagenics Limited For more information visit http://www.researchandmarkets.com/research/b9...cated_skin
GSK: 43.17 (-0.17)
Global Acute Pain Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/k9flzp/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Pain Overview - Therapeutics Development - Pipeline Products for Acute Pain - Overview - Pipeline Products for Acute Pain - Comparative Analysis - Acute Pain - Therapeutics under Development by Companies - Acute Pain - Therapeutics under Investigation by Universities/Institutes - Acute Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Pain - Products under Development by Companies - Acute Pain - Products under Investigation by Universities/Institutes - Acute Pain - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - Amorsa Therapeutics Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - AskAt Inc. - Cara Therapeutics, Inc. - Centrexion Corporation - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Dompe Farmaceutici S.p.A. - Grunenthal GmbH - INSYS Therapeutics, Inc. - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt Plc - MEDRx Co., Ltd. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Orexo AB - Orion Oyj - Pacira Pharmaceuticals, Inc. - Phosphagenics Limited - Recro Pharma, Inc. - Shulov Innovative Science Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. For more information visit http://www.researchandmarkets.com/research/k9flzp/acute_pain
ACRX: 2.69 (unch), KMPH: 4.32 (+0.34), NKTR: 14.40 (+0.17), INSY: 13.47 (+0.53), AVXL: 5.89 (-0.22), PCRX: 33.48 (-0.25), REPH: 8.18 (+0.23), PTIE: 2.17 (-0.02)
Phosphagenics Initiates Arbitration against Mylan
BusinessWire - Wed Jan 06, 6:00AM CST
Australian biotechnology company, Phosphagenics Limited (ASX
OH; OTCQX PGNY), announced today that it has commenced legal action against Mylan Laboratories Limited (Mylan), a wholly-owned subsidiary of Mylan Incorporated, by filing notices of arbitration at the Singapore International Arbitration Centre. MYL: 43.48 (+0.24)
Osteoarthritis Pain Therapeutics Pipeline Review, H2 2015 - 29 Companies & 50 Drug Profiles
M2 - Thu Dec 17, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/v8nbgw/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Allergan Plc - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bone Medical Limited - Centrexion Corporation - Convergence Pharmaceuticals Ltd. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Flexion Therapeutics, Inc. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA Drug Profiles - (lidocaine hydrochloride tetracaine hydrochloride) - (naltrexone hydrochloride oxycodone hydrochloride) SR - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - capsaicin - cebranopadol - celecoxib - CGS-125 - CR-4056 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - MEDI-7352 - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A For more information visit http://www.researchandmarkets.com/research/v8...oarthritis
FLXN: 15.40 (+0.43), PFE: 35.57 (+0.36), AMGN: 154.28 (+2.13), AMPE: 1.29 (unch), LLY: 78.95 (+0.20), NKTR: 14.40 (+0.17), AGN: 234.02 (+2.93), AZN: 30.42 (+0.23), ABBV: 62.71 (+0.80), POZN: 5.94 (-0.43), REGN: 358.50 (+9.27), PTIE: 2.17 (-0.02)
The Anesthetic Effect Pipeline Review, H2 2015 - 16 Companies & 24 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/25xt8p/anesthetic_effect) has announced the addition of the "Anesthetic Effect - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anesthetic Effect, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anesthetic Effect and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Drug Profiles - (lidocaine hydrochloride phenylephrine hydrochloride tropicamide) - (tetracaine hydrochloride oxymetazoline hydrochloride) - ABP-700 - ADV-6209 - alphaxalone - bupivacaine hydrochloride - carboetomidate - Gabafol - HSK-3486 - lidocaine hydrochloride ER - LT-1121 - LT-1123 - methoxycarbonyl carboetomidate - methoxycarbonyl etomidate - neosaxitoxin - PB-5109 - PHY-301 - propofol - propofol microemulsion - propofol-DM - remimazolam - remimazolam - Small Molecules to Inhibit NMDA Receptor for Anaesthesia - sugammadex sodium Companies Mentioned - Advicenne Pharma - Biolab Sanus Farmaceutica Ltda. - Drawbridge Pharmaceuticals Pty Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Juniper Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Lipicard Technologies Limited - Merck & Co., Inc. - NanoMedex Pharmaceuticals, Inc. - Paion AG - Phosphagenics Limited - Physica Pharma SAS - Proteus SA - Sphaera Pharma Pvt. Ltd. - Taiwan Liposome Company, Ltd. - The Medicines Company For more information visit http://www.researchandmarkets.com/research/25...tic_effect
MRK: 57.94 (+0.33), JNP: 6.97 (-0.04)
Global Burns Therapeutics Pipeline Review 2015
M2 - Thu Dec 03, 7:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/phkvtr/burns_pipeline) has announced the addition of the "Burns - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burns, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burns and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adocia - AlgiPharma AS - Biogenomics Limited - Birken AG - CytoTools AG - Destiny Pharma Limited - HanAll Biopharma Co., Ltd. - Kuros Biosurgery AG - MediWound Ltd. - Novan, Inc. - Novartis AG - Pherecydes Pharma SA - Phosphagenics Limited - Se-cure Pharmaceuticals Ltd. - Stratatech Corporation - USV Limited - Vida Therapeutics Inc. - Xiber Science GmbH For more information visit http://www.researchandmarkets.com/research/ph...s_pipeline
MDWD: 7.86 (-0.03), NVS: 82.71 (+0.20)
ANI Pharmaceuticals Appoints Peter A. Lankau to Its Board of Directors
PR Newswire - Tue Oct 13, 7:00AM CDT
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) announced today the appointment of Peter A. Lankau to the Company's Board of Directors to fill the existing vacancy in the Board. Mr. Lankau has over 30 years of management experience in developing and commercializing pharmaceutical products. ENDP: 16.98 (+1.39), ANIP: 57.31 (+1.49)
Acne Vulgaris Pipeline Review 2015 - 40 Companies & 53 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mtb2tv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advancell - Allergan, Inc. - AndroScience Corporation - Biomar Microbial Technologies - Braintree Laboratories, Inc. - Brickell Biotech, Inc. - Celtaxsys, Inc. - Cosmo Pharmaceuticals S.p.A - Cutanea Life Sciences - Delenex Therapeutics AG - Deltanoid Pharmaceuticals Inc. - Dermira Inc. - ELORAC, Inc. - Ensoltek Co., Ltd. - Foamix Pharmaceuticals Ltd. - Galderma S.A. - GlaxoSmithKline plc - Helix BioMedix, Inc. - Hovione FarmaCiencia SA - Kasiak Research Pvt. Ltd. - Lee's Pharmaceutical Holdings Limited - Maruho Co., Ltd. - Nabriva Therapeutics AG - Novabiotics Ltd - Novan, Inc. - OrigImm e.U. - Paratek Pharmaceuticals, Inc. - Phosphagenics Limited - Photocure ASA - Provectus Biopharmaceuticals, Inc. - QLT Inc. - RestorGenex Corporation - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Telesso Technologies Limited - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mt...e_vulgaris
QLTI: 1.44 (+0.02), FOMX: 6.60 (+0.25), GSK: 43.17 (-0.17), PRTK: 13.67 (-0.24), AGN: 234.02 (+2.93), PVCT: 0.37 (unch), DERM: 29.93 (+0.68), NBRV: 7.58 (+0.08)
Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics Pipeline Review, H1 2015 - 7 Companies & 11 Drug Profiles
M2 - Thu Jul 09, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vw27k3/complicated_skin) has announced the addition of the "Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cempra, Inc. - CrystalGenomics, Inc. - Debiopharm International S.A. - Dong-A Socio Group - GlaxoSmithKline plc - Melinta Therapeutics, Inc - Phosphagenics Limited Drug Profiles - CG-400549 - Debio-1450 - Debio-1452 - delafloxacin - fusidic acid - GSK-2140944 - iclaprim mesylate - lanopepden - Small Molecule for Skin Infections - Small Molecules to Inhibit DHFR for Infectious Diseases - tedizolid phosphate For more information visit http://www.researchandmarkets.com/research/vw...cated_skin
GSK: 43.17 (-0.17), CEMP: 17.09 (+0.60)
Seborrhea Pipeline Review, H1 2015 - 4 Companies & 6 Drug Profiles
M2 - Fri Jun 12, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pvb5km/seborrhea) has announced the addition of the "Seborrhea - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Seborrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seborrhea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Biomar Microbial Technologies - EpiPharm AG - Maruho Co., Ltd. - Phosphagenics Limited Drug Profiles - A-101 - EPI-SK14 - IB-07A081 - IB-07A085 - ketoconazole - lanoconazole For more information visit http://www.researchandmarkets.com/research/pvb5km/seborrhea
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 10.29 (-0.50), FOMX: 6.60 (+0.25), PVCT: 0.37 (unch), JNJ: 121.29 (-0.01), DERM: 29.93 (+0.68), ANAC: 99.06 (-0.14), XNCR: 18.93 (-0.06), REGN: 358.50 (+9.27), AQXP: 7.39 (+0.77), BMY: 73.78 (+0.23), GSK: 43.17 (-0.17), VRX.TO: 26.05 (-0.24), CBPO: 107.18 (+0.86), MRK: 57.94 (+0.33), CCXI: 4.74 (+0.25), CLTX: 36.01 (+16.34), CELGZ: 1.40 (-0.06), NVS: 82.71 (+0.20)
Seborrhea Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Fri Jan 02, 4:30PM CST
The report "Seborrhea Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Seborrhea. Seborrhea is a common skin problem. It causes a red, itchy rash and white scales. It particularly affects the sebaceous-gland-rich areas of skin such as scalp, face and torso. Seborrhoeic dermatitis symptoms appear gradually and usually the first signs are flaky skin and scalp. Adults of all ages may develop seborrhea, too, especially on the scalp and face. Complete Report is Available @ http://www.reportsnreports.com/reports/321896...-2014.html .
VRX.TO: 26.05 (-0.24)
(0)
(0)
